Focus: GEMMA Biotherapeutics is a gene therapy-focused biotech company headquartered in Philadelphia developing treatments for rare genetic diseases. The company is early-stage with three Phase 1/2 programs across neurodegenerative and lysosomal storage disorders.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Best suited for early-career professionals or specialists seeking deep gene therapy expertise with high risk tolerance in a capital-dependent environment.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for GEMMA Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GEMMA Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles